|
Apr 27, 2023
|
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
– First-quarter 2023 total revenue of $220 million , representing 48% year-over-year growth - – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – SOUTH PLAINFIELD, N.J. , April 27, 2023 /PRNewswire/ -- PTC Therapeutics, Inc.
|
|
|
Apr 13, 2023
|
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
SOUTH PLAINFIELD, N.J. , April 13, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, April 27 ,
|
|
|
Mar 28, 2023
|
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , March 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023 , the company approved non-statutory stock options to purchase an aggregate of 58,465 shares of its common stock and 29,710 restricted stock units ("RSUs"), each
|
|
|
Mar 24, 2023
|
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
- Chief Operating Officer Matthew Klein , M.D., M.S., F.A.C.S. to become Chief Executive Officer and join the Board of Directors – - Conference call to be held today, Fri., March 24 th at 8:30 am ET - SOUTH PLAINFIELD, N.J. , March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ).
|
|
|
Feb 21, 2023
|
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– 2022 total revenue of $699 million , representing 30% year-over-year growth, or $740 million and 37% growth at CER* – – Guidance for full-year 2023 total revenue of $940 million to $1 billion reaffirmed – – Four important study readouts expected in first half of 2023, three of them
|
|
|
Feb 21, 2023
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Raymond James 44 th Annual Institutional Investor Conference Monday, March 6 , at 8:05 a.m.
|
|
|
Feb 07, 2023
|
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday,
|
|
|
Feb 03, 2023
|
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of
|
|
|
Feb 02, 2023
|
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Feb. 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB Securities Global Biopharma Conference Tuesday, Feb. 14 at 9:20 a.m.
|
|
|
Jan 19, 2023
|
NICE Recommends Reimbursement for Translarna™
- Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final
|
|
